Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

cured notes125,000125,000Capital lease obligations, less current portion6,0258,049Liability related to receipt of refundable milestone payment70,00070,000Liability related to sale of future royalties, less current portion121,431121,520Deferred revenue, less current portion88,91882,384Other long-term liabilities17,76819,256Total liabilities513,497524,430Commitments and contingenciesStockholders' equity (deficit) :Preferred stock--Common stock1211Capital in excess of par value1,776,7461,643,660Accumulated other comprehensive loss(887)(1,181)Accumulated deficit(1,811,231)(1,732,393)Total stockholders' equity (deficit) (35,360)(89,903)Total liabilities and stockholders' equity (deficit) $
478,137
$
434,527
(1) The consolidated balance sheet at December 31, 2013 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(I
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015  Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in ... cancer, today announced that James A. Joyce , ... corporate overview at the 27th Annual ROTH Conference on ... was previously scheduled to present at 5:30 pm Pacific ... held at The Ritz-Carlton Hotel in Laguna ...
(Date:3/6/2015)... March 6, 2015  AbbVie (NYSE: ABBV ... Conference on Thursday, March 12, 2015. Richard A. ... in a question and answer session at 8:30 a.m. ... the presentation will be accessible through AbbVie,s Investor Relations ... of the session will be available later that day. ...
(Date:3/6/2015)... WOONSOCKET, R.I. , March 6, 2015 ... Chief Medical Officer of CVS Health (NYSE: ... on Health in Washington, D.C. ... a critical role in addressing health care cost and ... stress.  After making CVS/pharmacy the first national pharmacy chain ...
Breaking Medicine Technology:Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 3
(Date:3/6/2015)... March 06, 2015 Follow us ... the pharmacokinetics of a drug refers to testing of ... inside an organism. When toxicity studies are clubbed together ... or ADME/Tox. Increasing focus on lowering costs and time ... testing worldwide. The traditional drug development model uses toxicity ...
(Date:3/6/2015)... 06, 2015 Parents need to start ... of substance use disorders. School programs like DARE, or ... successful. NOPE, or Narcotics Overdose Prevention and Education has ... Healthline News on Feb. 27th. As teens ... opiate drugs, drug prevention proponents are lobbying Florida to ...
(Date:3/6/2015)... March 06, 2015 Johnson & Johnson ... verdict on March 5, 2015 in Superior Court in ... court documents, a jury of 12 awarded Mrs. Perry ... being implanted with an Ethicon TVT Abbrevo plastic sling ... and three women also awarded $5 million in punitive ...
(Date:3/6/2015)... DC (PRWEB) March 06, 2015 Magellan ... nation’s only comprehensive source for key trends and statistics ... spend, medical injectables. Executives from Magellan Rx Management will ... Trend Report: Discover Your Hidden Specialty Drug Spend,” a ... Information Services, Inc. , Specialty drug spend makes up ...
(Date:3/6/2015)... The Gluten-Free Certification Program (GFCP), ... pleased to announce that Dufflet Pastries, the ground-breaking ... their product line of gluten-free treats certified by ... as satisfying as any of their other desserts! ... contains hydrogenated fats or oils, artificial flavours, colours ...
Breaking Medicine News(10 mins):Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4
... Technologies, makers,of a gamma imaging system optimized for ... with Amerinet, a leading national,group purchasing organization. Effective ... healthcare providers and their,patients, access to the Dilon ... early stage breast cancers., "Dilon Technologies is ...
... Dynamics Company,Ltd.) (TSX: IDL), the global leader in ... announced the appointment of Mr. Rodolfo,Gutierrez as Vice ... a veteran of the imaging industry, will be ... development, distribution,service and product sales in the region., ...
... Philadelphia, PA, July 16, 2008 Anxiety is a ... can develop into a disabling disorder of excessive and ... posttraumatic stress disorder. Effective treatments are available and ... "it makes intuitive sense that combining these two treatments ...
... are taking adequate steps to address the cost of ... York, California and North Carolina are facing tens ... myths and realities of this potential crisis are laid ... Robert Clark, a professor of economics and of management, ...
... Immunosyn,Corporation (OTC Bulletin Board: IMYN) announced today that ... is anticipated to begin,shortly through Renewed Hope Clinic ... exclusive license agreement for the,administration and distribution of ... Laboratories, LLC., Immunosyn has been advised by ...
... cross contaminations including Norovirus ... ... Shield LLC has begun,shipping a new family of fully submersible, 108 ... risk,of worldwide cross contaminations, including Norovirus and the "superbug,",MRSA. According to ...
Cached Medicine News:Health News:Dilon Technologies Signs Amerinet for Breast-Specific Gamma Imaging 2Health News:IDC appoints new Vice President for Latin America 2Health News:D-cycloserine may improve behavioral therapy treatment for anxiety 2Health News:Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah 2Health News:Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah 3Health News:Seal Shield to Launch World's First Dishwasher Safe, Antimicrobial Keyboard with Multi-Language Support for International Markets 2
Denman brown nucleus cracker with 30 angled shafts, tip to angle length 14.5 mm. Standard cross action handle. 1.1 mm x 1.2 mm paddle style tips....
Nucleus cracker....
Removal Forceps, very fine pointed tips, with textured jaws, ideal for grasping wet sutures....
Forceps, delicate, straight....
Medicine Products: